Chronic Hepatitis DeltaNCT04170452
Study the Content of the HBV DNA in Liver Biopsy in the Patients Chronic Hepatitis Delta
An observational study of Chronic Hepatitis Delta and Liver Biopsy, run by Tokhirbek Dolimov at 1 site in Uzbekistan.
Trial summary
Study the content of the HBV DNA in liver biopsy in the patients with the Chronic Hepatitis Delta in absence of the HBV DNA in the blood plasma Read more about this study
- Who is it for?
- Ages 18 to 40 years
- Conditions the study is for
- Chronic Hepatitis Delta, Liver Biopsy
- What is being tested?
- liver biopsy
- Type of treatment
- Pill or oral medicine, Surgery or procedure
- How many people
- 30 participants
- Where
- 1 siteUzbekistan
- Study dates
- 10 Oct 2019to 1 Jun 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- All sexes
- No healthy volunteers
- Adult
Study population: All patients with chronic viral hepatitis delta
Who may be able to join
- patients with the Chronic Hepatitis Delta in absence of the HBV DNA in the blood plasma
Who cannot join
- patient's with the Chronic Hepatitis Delta in absence of the HBV DNA in the blood plasma but: inability to remain still and to maintain brief expiration for the procedure, suspected vascular lesion (eg, hemangioma), bleeding tendency (eg, INR > 1.2 despite receiving vitamin K, bleeding time > 10 min), severe thrombocytopenia (< 50,000/mL)
Trial locations and contacts
1 site in 1 country.
About this study
Official title: HBV DNA Replication in Hepatocytes in HBV and HDV Co-infection
Study the content of the HBV DNA in liver biopsy in the patients with the Chronic Hepatitis Delta in absence of the HBV DNA in the blood plasma
Read the detailed description
Investigators interpreted the data of several researchers that studied suppression of the HBV DNA replication in the Delta infection within this article. Co-infection and superinfection of hepatitis B virus (HBV) with hepatitis delta virus (HDV) leads to suppression of HBV replication in both patients as well as animals and cell models. The mechanisms underlying this suppression were not fully studied before.
Jaw-Ching Wu et al. described the suppression of HBV DNA replication during HBV and HDV co-infection for the first time in 1991. The results of studies in the liver experimental models HuH-7 clearly demonstrated that one delta HDV antigen can suppress the expression of HBV RNA.
Dulce Alfaiate et al. conducted studies on the experimental models proving that HBV replication markers, including HBeAg, total HBV DNA and pregenomic RNA were significantly reduced after superinfection with HDV which confirming the effect of HDV on HBV. But thereby, the levels of circularly covalently closed levels of HBV DNA (cccDNA) and HBsAg were not decreased. At the peak of HDV-RNA accumulation and appearance of the interference in HBV replication, a strong I type IFN response was observed with highly induced genes stimulated by the interferon, RSAD2 (Viperin) and IFI78 (MxA). Both mono- and superinfected dHepaRG cells maintained strong intracellular replication of HDV, which was accompanied with the strong secretion of infectious HDV virions.
The following analysis of the data in the experimental studies by Zhenfeng Zhang et al. proved that the HDV virus activated strongly IFN-β and IFN-λ in the hepatocyte cell lines. The active HDV replication induces the IFN-β/λ response. Unlike hepatitis B virus, hepatitis D virus infection causes a strong IFN-β/λ response in the innate immunocompetent cell lines. The activated IFN did not suppress replication of hepatitis D virus in vitro, which indicatesthat Delta hepatitis virus is resistant to the self-induced innate immune responses and therapeutic treatment for IFN.
According to the authors, this stimulation of the synthesis of endogenous IFN-β and IFN-λ inside the hepatocyte by the HDV virus caused suppression of the HBV virus replication.
The following study, conducted Paolo Pugnale et al., in Huh-7 human hepatoma cells demonstrates that HDV can disrupt the IFN-α-stimulated JAK-STAT signaling pathway (a mediating protein ensuring cell response to the signals from the interleukin receptors and growth factors). The mechanism adopted by HDV to interfere with IFN-α/β signaling is based on inhibition of the tyrosine phosphorylation of STAT1, STAT2 and Tyk2 receptor-bound kinase without reducing expression levels of the IFN receptor subunits or other components in the signaling cascade. These results indicate that the HDV virus develops a strategy to counteract the actions of I type IFN. This study may be useful for a better understanding of the observed resistance to IFN in the chronic patients with the Chronic Hepatitis Delta and may provide the useful data for defining new strategies for antiviral intervention.
However, it should be noted that KatashibaY. in his research indicates that IFN is mainly stimulated in case of infection with the DNA-containing viruses, while IL-12 induction predominates in case of the RNA-containing infections. Since HDV consists of a single-stranded RNA molecule, it is not expected to stimulate IFN.
Given the above stated disagreements in the results of the authors' studies, Investigators decided to examine the patients with the Chronic Hepatitis Delta when the HBV DNA was not detected in the blood during examination by PCR.
- Conditions
- Chronic Hepatitis Delta, Liver Biopsy
- Being tested
- liver biopsy
- Keywords
- Viral hepatitis B, HBV DNA, Viral hepatitis Delta, iver biopsy, PCR
- Medical subject headings
- Hepatitis D, Chronic, Hepatitis B
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
liver biopsyProcedure or surgery
Pre-procedure assessment of the liver with ultrasound should be performed for planning positioning and needle entrance point. Supine, oblique, or total left lateral decubitus are the possible positioning of the patient - it is important to make sure that the patient is comfortable and can remain still in that position. Assessing if the procedure will be performed under breath held and practice this with the patient. Marking of the entrance point on the skin is advised to aid the skin cleaning and dressing. A time-out should be performed by this stage. Skin site is prepped and draped to ensure asepsis. Ocal anaesthesia is infiltrated under the skin abdominal wall/intercostal space until the liver capsule. Entrance point is created with a scalpel. Using the freehand technique the needle is advanced under ultrasound guidance during the entire course of the biopsy. The needle tip must always cross the capsule prior to deploying the cutting device.
| Study group | Role | What they receive |
|---|---|---|
| Chronic Hepatitis Delta patients | Patients infected with delta virus Receives: Procedure: liver biopsy |
What is being measured
The primary outcome is the main question the study is designed to answer.
The study the content of the HBV DNA in liver biopsy
In this study we are going to do liver biopsy in 30 patients with a diagnosis of Chronic Viral Hepatitis B and Delta.
Measured: up to 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Nov 2019
- Study start10 Oct 2019
- Primary completion1 Jun 2020 (estimated)
- Study completion1 Jun 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Hepatitis DeltaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Tokhirbek Dolimov
- Sponsor type
- Other government
- Responsible party
- Sponsor-investigator, Tokhirbek Dolimov, Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan
- Investigators
- Nariman Gulyamov, DSci, Study chair, Research institute of epidemiology, microbiology and infectious diseases
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04170452
- Sponsor's protocol ID
- ADCC - 15.21.1
- Status last verified
- Nov 2019
- First submitted
- 15 Nov 2019
- Last updated
- 21 Nov 2019
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Nov 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- HBV DNA Replication in Hepatocytes in HBV and HDV Co-infection
- ClinicalTrials.gov ID
- NCT04170452
- Acronym / sponsor ID
- ADCC - 15.21.1
- Conditions
- Chronic Hepatitis Delta, Liver Biopsy
- Keywords
- Viral hepatitis B, HBV DNA, Viral hepatitis Delta, iver biopsy, PCR
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Tokhirbek DolimovOther government
- Study start
- 10 Oct 2019 (actual)
- Primary completion
- 1 Jun 2020 (estimated)
- Study completion
- 1 Jun 2020 (estimated)
- First posted
- 20 Nov 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Study the content of the HBV DNA in liver biopsy in the patients with the Chronic Hepatitis Delta in absence of the HBV DNA in the blood plasma
Detailed description
Investigators interpreted the data of several researchers that studied suppression of the HBV DNA replication in the Delta infection within this article. Co-infection and superinfection of hepatitis B virus (HBV) with hepatitis delta virus (HDV) leads to suppression of HBV replication in both patients as well as animals and cell models. The mechanisms underlying this suppression were not fully studied before.
Jaw-Ching Wu et al. described the suppression of HBV DNA replication during HBV and HDV co-infection for the first time in 1991. The results of studies in the liver experimental models HuH-7 clearly demonstrated that one delta HDV antigen can suppress the expression of HBV RNA.
Dulce Alfaiate et al. conducted studies on the experimental models proving that HBV replication markers, including HBeAg, total HBV DNA and pregenomic RNA were significantly reduced after superinfection with HDV which confirming the effect of HDV on HBV. But thereby, the levels of circularly covalently closed levels of HBV DNA (cccDNA) and HBsAg were not decreased. At the peak of HDV-RNA accumulation and appearance of the interference in HBV replication, a strong I type IFN response was observed with highly induced genes stimulated by the interferon, RSAD2 (Viperin) and IFI78 (MxA). Both mono- and superinfected dHepaRG cells maintained strong intracellular replication of HDV, which was accompanied with the strong secretion of infectious HDV virions.
The following analysis of the data in the experimental studies by Zhenfeng Zhang et al. proved that the HDV virus activated strongly IFN-β and IFN-λ in the hepatocyte cell lines. The active HDV replication induces the IFN-β/λ response. Unlike hepatitis B virus, hepatitis D virus infection causes a strong IFN-β/λ response in the innate immunocompetent cell lines. The activated IFN did not suppress replication of hepatitis D virus in vitro, which indicatesthat Delta hepatitis virus is resistant to the self-induced innate immune responses and therapeutic treatment for IFN.
According to the authors, this stimulation of the synthesis of endogenous IFN-β and IFN-λ inside the hepatocyte by the HDV virus caused suppression of the HBV virus replication.
The following study, conducted Paolo Pugnale et al., in Huh-7 human hepatoma cells demonstrates that HDV can disrupt the IFN-α-stimulated JAK-STAT signaling pathway (a mediating protein ensuring cell response to the signals from the interleukin receptors and growth factors). The mechanism adopted by HDV to interfere with IFN-α/β signaling is based on inhibition of the tyrosine phosphorylation of STAT1, STAT2 and Tyk2 receptor-bound kinase without reducing expression levels of the IFN receptor subunits or other components in the signaling cascade. These results indicate that the HDV virus develops a strategy to counteract the actions of I type IFN. This study may be useful for a better understanding of the observed resistance to IFN in the chronic patients with the Chronic Hepatitis Delta and may provide the useful data for defining new strategies for antiviral intervention.
However, it should be noted that KatashibaY. in his research indicates that IFN is mainly stimulated in case of infection with the DNA-containing viruses, while IL-12 induction predominates in case of the RNA-containing infections. Since HDV consists of a single-stranded RNA molecule, it is not expected to stimulate IFN.
Given the above stated disagreements in the results of the authors' studies, Investigators decided to examine the patients with the Chronic Hepatitis Delta when the HBV DNA was not detected in the blood during examination by PCR.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Chronic Hepatitis Delta patients | – | Procedure: liver biopsyPatients infected with delta virus |
Who may qualify
- Ages
- 18 to 40 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- All patients with chronic viral hepatitis delta
Key inclusion criteria (1 listed)
- patients with the Chronic Hepatitis Delta in absence of the HBV DNA in the blood plasma
Key exclusion criteria (1 listed)
- patient's with the Chronic Hepatitis Delta in absence of the HBV DNA in the blood plasma but: inability to remain still and to maintain brief expiration for the procedure, suspected vascular lesion (eg, hemangioma), bleeding tendency (eg, INR > 1.2 despite receiving vitamin K, bleeding time > 10 min), severe thrombocytopenia (< 50,000/mL)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| liver biopsyPre-procedure assessment of the liver with ultrasound should be performed for planning positioning and needle entrance point. Supine, oblique, or total left lateral decubitus are the possible positioning of the patient - it is important to make sure that the patient is comfortable and can remain still in that position. Assessing if the procedure will be performed under breath held and practice this with the patient. Marking of the entrance point on the skin is advised to aid the skin cleaning and dressing. A time-out should be performed by this stage. Skin site is prepped and draped to ensure asepsis. Ocal anaesthesia is infiltrated under the skin abdominal wall/intercostal space until the liver capsule. Entrance point is created with a scalpel. Using the freehand technique the needle is advanced under ultrasound guidance during the entire course of the biopsy. The needle tip must always cross the capsule prior to deploying the cutting device. | Procedure or surgery | Chronic Hepatitis Delta patients |
Primary outcome
The study the content of the HBV DNA in liver biopsy
Time frame: up to 3 months
In this study we are going to do liver biopsy in 30 patients with a diagnosis of Chronic Viral Hepatitis B and Delta.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Nov 2019.
- Individual participant dataSharing planned: No
Related trials for Chronic Hepatitis Delta
RecruitingObservational study
Evaluation of Patients With Liver Disease
Hepatitis D, Hepatitis C
RecruitingObservational study
Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD)
Hepatitis D
Active, not recruitingPhase 3
A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection
Viral Hepatitis
Not yet recruitingPhase 3
Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D
Hepatitis D, Chronic
Active, not recruitingPhase 2/3
A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection
Chronic Hepatitis D Infection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nariman Gulyamov, DSci study chair
Research institute of epidemiology, microbiology and infectious diseases
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Chronic Hepatitis Delta and Liver Biopsy, run by Tokhirbek Dolimov at 1 site in Uzbekistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 21 Nov 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Uzbekistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The study the content of the HBV DNA in liver biopsy (time frame: up to 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Nov 2019.